Geode Capital Management’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-138,465
| Closed | -$37K | – | 5037 |
|
|
2022
Q3 | $37K | Hold |
138,465
| – | – | ﹤0.01% | 4822 |
|
|
2022
Q2 | $50K | Hold |
138,465
| – | – | ﹤0.01% | 4777 |
|
|
2022
Q1 | $94K | Hold |
138,465
| – | – | ﹤0.01% | 4682 |
|
|
2021
Q4 | $319K | Hold |
138,465
| – | – | ﹤0.01% | 4273 |
|
|
2021
Q3 | $634K | Buy |
138,465
+6,344
| +5% | +$27.9K | ﹤0.01% | 3918 |
|
|
2021
Q2 | $586K | Sell |
132,121
-97,294
| -42% | -$495K | ﹤0.01% | 3870 |
|
|
2021
Q1 | $1.67M | Buy |
229,415
+24,136
| +12% | +$199K | ﹤0.01% | 3342 |
|
|
2020
Q4 | $1.57M | Buy |
205,279
+69,237
| +51% | +$463K | ﹤0.01% | 3206 |
|
|
2020
Q3 | $1.24M | Buy |
136,042
+324
| +0.2% | +$2.46K | ﹤0.01% | 3125 |
|
|
2020
Q2 | $1.15M | Buy |
135,718
+33,159
| +32% | +$218K | ﹤0.01% | 3100 |
|
|
2020
Q1 | $506K | Buy |
102,559
+7,590
| +8% | +$59K | ﹤0.01% | 3267 |
|
|
2019
Q4 | $683K | Buy |
94,969
+2,019
| +2% | +$18.2K | ﹤0.01% | 3404 |
|
|
2019
Q3 | $1M | Buy |
92,950
+799
| +0.9% | +$8.55K | ﹤0.01% | 3235 |
|
|
2019
Q2 | $1.2M | Buy |
92,151
+29,318
| +47% | +$389K | ﹤0.01% | 3179 |
|
|
2019
Q1 | $620K | Buy |
62,833
+2,634
| +4% | +$24.5K | ﹤0.01% | 3348 |
|
|
2018
Q4 | $626K | Buy |
+60,199
| New | +$727K | ﹤0.01% | 3283 |
|
Geode Capital Management's LOGC Position: Q4 2022 in Review
Geode Capital Management sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 138,465 shares — an estimated $37K sold.
Geode Capital Management first reported a position in LOGC in Q4 2018 and held it in 16 quarters. The position peaked at $1.67M in Q1 2021. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.
- Geode Capital Management reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
- Geode Capital Management sold 138,465 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $37K.
- Geode Capital Management first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 16 quarters.
- Geode Capital Management's LogicBio Therapeutics, Inc. Common Stock position peaked at $1.67M in Q1 2021.
- 0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.
Based on Geode Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.